Dr. Bilal H. Naqvi, MD | Woodbury, MN ...

Dr. Bilal H. Naqvi

Claim this profile

Marshfield Clinic-Minocqua Center

Studies Oropharyngeal Carcinoma
Studies Fallopian Tube Carcinoma
7 reported clinical trials
23 drugs studied

Area of expertise

1

Oropharyngeal Carcinoma

Bilal H. Naqvi has run 2 trials for Oropharyngeal Carcinoma. Some of their research focus areas include:

p16 positive
Stage IV
p16 negative
2

Fallopian Tube Carcinoma

Bilal H. Naqvi has run 2 trials for Fallopian Tube Carcinoma. Some of their research focus areas include:

p16 positive
Stage IV
p16 negative

Affiliated Hospitals

Image of trial facility.

Marshfield Clinic-Minocqua Center

Image of trial facility.

Marshfield Medical Center-EC Cancer Center

Clinical Trials Bilal H. Naqvi is currently running

Image of trial facility.

Duvelisib/CC-486 + Chemotherapy

for Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.

Recruiting

1 award

Phase 2

27 criteria

Image of trial facility.

Cabozantinib + Nivolumab

for Advanced Skin and Head & Neck Cancers

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.

Recruiting

1 award

Phase 2

More about Bilal H. Naqvi

Clinical Trial Related

6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Bilal H. Naqvi has experience with

  • Cyclophosphamide
  • Prednisone
  • Cisplatin
  • Durvalumab
  • Bendamustine Hydrochloride
  • Lenalidomide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Bilal H. Naqvi specialize in?

Is Bilal H. Naqvi currently recruiting for clinical trials?

Are there any treatments that Bilal H. Naqvi has studied deeply?

What is the best way to schedule an appointment with Bilal H. Naqvi?

What is the office address of Bilal H. Naqvi?

Is there any support for travel costs?